Literature DB >> 22441522

[Gender-related aspects of returning to work in cancer survivors. A systematic review].

A Ullrich1, H M Böttcher, C Bergelt.   

Abstract

Due to improved prognosis most cancer survivors are nowadays able to return to work. This review explored gender-related differences in work-related outcomes after cancer. A systematic search of studies on work-related issues in cancer survivors published between January 2001 and July 2011 was conducted. 44 original publications met the inclusion criteria (adult cancer survivors, focus on work-related outcomes, gender-specific report of results). The results of these studies indicate that impaired work ability is more common among female cancer survivors than among male cancer survivors as well as the reduction of working hours and income losses. Supportive work environments seem to be particularly helpful for the successful and long-lasting re-integration of female survivors. More systematic research and separate analyses for women and men are needed to fully comprehend gender differences in work-related outcomes. Broader knowledge can then be helpful in creating gender-specific return-to-work interventions.

Entities:  

Mesh:

Year:  2012        PMID: 22441522     DOI: 10.1007/s00103-012-1454-y

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  2 in total

1.  Outcomes across the return-to-work process in PC survivors attending a rehabilitation measure-results from a prospective study.

Authors:  Anneke Ullrich; Hilke M Rath; Ullrich Otto; Christa Kerschgens; Martin Raida; Christa Hagen-Aukamp; Corinna Bergelt
Journal:  Support Care Cancer       Date:  2017-07-11       Impact factor: 3.603

2.  Return to work in prostate cancer survivors - findings from a prospective study on occupational reintegration following a cancer rehabilitation program.

Authors:  Anneke Ullrich; Hilke Maria Rath; Ullrich Otto; Christa Kerschgens; Martin Raida; Christa Hagen-Aukamp; Corinna Bergelt
Journal:  BMC Cancer       Date:  2018-07-20       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.